title: Uterine adenocarcinoma after GnRH agonist treatment.
abstract: We report endometrial adenocarcinoma in two patients shortly after suspending GnRH-agonist treatment for menometrorrhagia and uterine fibromata.
authors.forename: S
authors.initials: S
authors.lastname: Dessole
authors.forename: G A
authors.initials: GA
authors.lastname: Ruiu
authors.forename: P L
authors.initials: PL
authors.lastname: Cherchi
authors.forename: G
authors.initials: G
authors.lastname: Ambrosini
mesh_terms: D000230:Adenocarcinoma / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007889:Leiomyoma / Q000188:drug therapy* / Q000473:pathology; D016729:Leuprolide / Q000008:administration & dosage / Q000009:adverse effects*; D008796:Metrorrhagia / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009215:Myometrium / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology; D017329:Triptorelin Pamoate / Q000008:administration & dosage / Q000009:adverse effects*; D014594:Uterine Neoplasms / Q000139:chemically induced* / Q000188:drug therapy* / Q000473:pathology
chemical_list: D018931:Antineoplastic Agents, Hormonal; D017329:Triptorelin Pamoate; D016729:Leuprolide